What is Synapticure?
Headquartered in Chicago, Illinois, Synapticure is dedicated to revolutionizing care for people living with Amyotrophic Lateral Sclerosis (ALS). The company's innovative approach brings personalized medical attention online and directly to patients' homes. Developed in collaboration with leading ALS clinicians and informed by the experiences of those living with the condition, Synapticure aims to set a new standard for comprehensive ALS care, addressing critical needs within the patient community.
How much funding has Synapticure raised?
Synapticure has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Series A
$25M
Angel/Seed (2022): $6M with participation from GV, Byers Capital, Adam Koppel, Lifeforce Capital Gp I, Joe Kraus, Martin Ventures, Y Combinator, Ron Conway, Gerald E. Bisbee, Jeff Huber, Ben and Divya Silbermann, Rohan Seth, and David Hodgson
Series A (2024): $25M led by GV, B Capital Group, RA Capital Management, and CVS Health
Key Investors in Synapticure
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations. They provide financial backing to promising startups and growth-stage businesses globally.
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors. They aim to support founders throughout the company-building lifecycle with a global presence.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics. They aim to partner with innovators to bring ideas from the lab to the clinic.
What's next for Synapticure?
The recent major strategic investment signifies a pivotal moment for Synapticure, positioning the company for accelerated growth and expanded service offerings. This capital will likely fuel advancements in their personalized care model, enhance technological infrastructure, and broaden their reach to more ALS patients and their families. The company's focus on a patient-centric, home-based model, supported by significant enterprise-level backing, suggests a strategic push to become a dominant force in specialized neurological care.
See full Synapticure company page
